Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
355
resultados
Última actualización
29/10/2026 [08:25:00]
Resultados 75 a 100 de 355
Resumen de: US20260309724A1
Methods and compositions for diagnosing brain injury, neurodegeneration; or a predisposition thereto, in a subject are provided. Particularly, the present invention relates to specific antigen antibody reactivities useful in diagnosing brain injury, neurodegeneration or a predisposition thereto, in a subject.
Resumen de: US20260308210A1
0000 A polypeptide capable of inhibiting Tau aggregation includes an amino acid sequence sharing between 20% and 99% sequence similarity with a structured core region of a pathological Tau filament, where the polypeptide is capable of binding to an end of a Tau fibril and reducing Tau aggregation or Tau seeding activity. The polypeptide may include an amino acid sequence derived from a microtubule-associated protein such as MAP2 or MAP4. Methods for inhibiting Tau aggregation in a biological sample include contacting the biological sample containing Tau with the polypeptide, where the polypeptide binds to an end of a Tau fibril and reduces Tau aggregation relative to a control sample.
Resumen de: WO2026209594A1
The present invention is directed to means for assessing whether a subject in need of an anti-amyloid therapy has or develops ARIA-E by determining an amount or a concentration of Amyloid-beta 42 (Aβ42) in a sample of the subject. Further, the present invention relates to the use of Aβ42 in the detection of ARIA-E.
Resumen de: WO2026212334A1
The present invention relates to an immunodiagnostic method using multiple biomarkers, which can improve diagnostic efficiency compared to conventional immunodiagnostic devices. The immunodiagnostic method comprises the steps of: setting a reference range for the level of biomarkers; collecting a human-derived sample from a subject to be tested; measuring two or more biomarkers in the sample so as to be individually identifiable, using detection media capable of distinguishing the biomarkers from each other; and selecting a sample in which the measured level of biomarkers falls outside the reference range.
Resumen de: WO2026209593A1
The present invention is directed to means for assessing whether a subject in need of an anti-amyloid therapy has or develops ARIA-E by determining an amount or a concentration of NfL in a sample of the subject. Further, the present invention relates to the use of NfL in the detection of ARIA-E.
Resumen de: WO2026209595A1
The present invention is directed to means for assessing whether a subject in need of an anti-amyloid therapy has or develops Amyloid- Related Imaging Abnormality - Edema (ARIA-E) by determining an amount or a concentration of one or more of the following biomarkers CD14, ACE2, MYOC, DCN, CTRC, MERTK, HMOX1, TNR, DKK3, SCGN, L1CAM, LPL, C1QA, F3, NPY, LEP, PGF, TEK, SPP1, and STREM2 in a sample of the subject. Further, the present invention relates to the use of one or more of the following biomarkers CD14, ACE2, MYOC, DCN, CTRC, MERTK, HMOX1, TNR, DKK3, SCGN, L1CAM, LPL, C1QA, F3, NPY, LEP, PGF, TEK, SPP1, and STREM2 in the detection of ARIA-E.
Resumen de: WO2026213117A1
In one aspect, methods for treating a subset of subjects suffering from schizophrenia/schizoaffective disorder exhibiting negative symptoms and/or cognitive deficits that include a) identifying a subject having increased inflammation connected with redox imbalance of olfactory epithelia, and b) treating the identified subject for schizophrenia and/or a schizoaffective disorder. In further aspects, methods of treating subjects with schizophrenia and related psychotic disorders include administration of Nrf2 activators. In further aspects, methods are provided for diagnosing, prognosing, and defining a treatment in response to nasal examination, including Alzheimer's disease and/or cognitive impairment.
Resumen de: US20260309671A1
Various examples are provided related to electrochemical biosensors, systems, and methods of use. A biomarker associated with a disease in a biological fluid sample can be detected by first contacting the biological fluid sample with a working electrode of an electrochemical biosensor. Next, one or more changes in an electronic property of the working electrode resulting from binding of the biomarker to the capture agent can be detected. Then, electrochemical data can be determined based at least in part on the one or more changes in the electronic property of the working electrode detected by the electrochemical biosensor. The electrochemical data can then be input into a machine-learning (ML) model trained to analyze the electrochemical data to determine a risk level associated with the disease. Finally, the risk level associated with the disease can be determined based at least in part on the ML model.
Resumen de: US20260309703A1
The present disclosure describes a diagnostic platform that combines CRISPR/Cas technology with electrochemiluminescence (ECL) or fluorescence detection for highly sensitive and specific identification of disease biomarkers, such as microRNAs and proteins, without the need for complex amplification processes.
Resumen de: WO2026213448A1
Methods are provided for the high yield and low-cost manufacture of highly pure tau proteins for use as substrates for tau seed amplification assays.
Resumen de: WO2026213047A1
Described herein are methods for analyzing microRNAs (miRNAs) derived from a population of extracellular vesicles (EVs) in a biological sample using next generation sequencing (NGS). The methods comprise isolating the population of EVs from a biological sample obtained from a subject, extracting RNA from the population of EVs, wherein the extracted RNA comprises one or more miRNAs, ligating one or more adapters to the extracted RNA to generate adapter-ligated RNA molecules, reverse transcribing the adapter-ligated RNA molecules to generate a complementary DNA (cDNA) library, amplifying the cDNA library, sequencing the amplified cDNA library using NGS to obtain sequencing reads, and analyzing the sequencing reads by a bioinformatic workflow.
Resumen de: US20260306430A1
Compositions, kits, and methods are disclosed for nutritional neurometabolic support and improved gut health using bioidentical D-beta-hydroxybutyric acid (D-BHB) to promote neurological wellness, mood stability and adaptive brain function during everyday life and during changes in neurologically acting medication regimens. The compositions comprise a salt-free, ester-free, alcohol-free D-BHB acid formulation optionally configured with vitamin B to raise circulating ketone levels, supply a preferred brain energy substrate, and support intestinal barrier integrity by improving tight junction function and reducing paracellular leakiness, thereby influencing gut-brain axis signaling. The compositions optionally incorporate B vitamins with vitamin B6 being a preferred embodiment to complement bioidentical D-BHB by supporting neurotransmitter synthesis and related gut-brain pathways. Kit (701) provides unit dose containers of bioidentical D-BHB, with or without B-vitamin supplementation and optional tapered pharmaceutical doses, together with optional software or AI-based tools configured to capture diet and mood data via smartphone and to generate guidance for nutritional and medication-taper support.
Resumen de: WO2026209799A1
The present application discloses a method of monitoring and/or determining the responsiveness of a subject's eye having capillary retinal perfusion dysfunction, to an administration of a first dose of Annexin A5 to the subject, wherein the method comprises assessing the health of the eye and/or assessing total plasma concentration of phosphatidylserine (PS) at about or within a week, 6 days, 5 days, 4 days, 3 days, 2 days or 1 day, of the administration of the first dose of the Annexin A5 to the subject. These methods permit the rapid stratification of subjects into appropriate treatment groups, and the early onset of a treatment regime that is therapeutically appropriate to the subject.
Resumen de: WO2026211690A1
The present invention addresses the problem of providing a method, a kit, and a biomarker for assisting diagnosis of schizophrenia or depression, and providing a method, a kit, and a biomarker for assisting differentiation from schizophrenia or depression. The present invention provides a method for assisting diagnosis of schizophrenia or depression, wherein the method comprises detecting cells having MS4A3 contained in a test sample.
Resumen de: WO2026212310A1
The present invention relates to a degenerative brain disease model and a method for constructing same and, more specifically, to a disease modeling technology for reproducing non-genetic (sporadic) Alzheimer's disease and cerebral amyloid angiopathy (CAA), which account for the majority of actual patients on the basis of a V-NAMO platform without relying on genetic mutations. Through a combined exposure strategy of amyloid beta oligomers in consideration of the characteristics of a scaffold, pathology in which amyloid plaques accumulate along actual vascular walls and the neurovascular unit is damaged is precisely implemented in vitro, thereby providing an innovative platform for research on mechanisms of degenerative brain diseases and preclinical efficacy evaluation of new drug candidates.
Resumen de: AU2025241870A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells (MSCs). The methods of treatment involve an administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive or quality-of-life function.
Resumen de: US20260309725A1
The invention relates to a nasal fluid sample obtained from a subject comprising the marker protein(s) β amyloid (Aβ), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for use in a method for the aid in diagnosis of neurodegenerative diseases and the use of a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for the aid in diagnosis of a neurodegenerative disease. The invention further relates to a method for the aid in diagnosis of a neurodegenerative disease in a subject/individual.
Resumen de: US20260309720A1
This invention relates to the detection of Tau protein in body fluids using biomarker peptides and their detection by Multiplexed Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) methods such as Selected Reaction Monitoring (SRM). In particular, the biomarker peptides are intended to distinguish between Tau protein produced by the Peripheral Nervous System and Tau protein produced by the Central Nervous System. This invention also relates to methods of using these peptide biomarkers for diagnosing and/or classifying the severity of a Neurodegenerative Disease, treatment of a Neurodegenerative Disease and assessing the efficacy of a treatment for a Neurodegenerative Disease, in particular for Tauopathies such as Alzheimer's disease. Also provided are a kit for diagnosing and/or classifying the severity of a Neurodegenerative disease, a kit for use in the treatment of a Neurodegenerative disease and a kit for assessing the efficacy of a treatment for a Neurodegenerative Disease in a subject.
Resumen de: US20260306484A1
The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.
Resumen de: US20260306662A1
0000 Transplantation of inhibitory neuron progenitors rekindles a targeted, time-limited phase of critical period plasticity within recipient brain areas. This restoration of youthful plasticity establishes a therapeutic environment conducive to circuit reorganization, consistently demonstrated to ameliorate cognitive and functional impairments. Remarkably, the mere overexpression of Calb1 in adult inhibitory neurons via viral vectors is adequate to reactivate critical period plasticity without the need for transplantation. Consequently, methodologies and compositions for augmenting Calb1 expression as a therapeutic avenue to reactivate plasticity are described herein.
Resumen de: US20260309718A1
0000 The present invention covers an in vitro method for evaluating the ability of a compound to disrupt or stabilize an interaction between one or more bait and one or more candidate prey in a eukaryotic cell. In addition, the present invention covers compounds identified by the in vitro method according to any one of the preceding claims, for use as a medicament.
Resumen de: US20260308202A1
Described herein are peptides and pharmaceutical compositions, e.g., for the treatment of inflammation. Further described herein are methods of treating patients for inflammation and/or infection with particularly efficacious treatments depending on the subject's level of fVEGF.
Resumen de: US20260309712A1
Improved antibodies for detection of phosphorylated RBL1, H1.5, LARP6, SUV39H1, and FAM53C have been developed. Assays using them to detect the biomarkers: P-T143 FAM53C, P-T202 LARP6, P-S988 RBL1, P-S17 H1.5, and P-S391 SU-V39H1, and diagnostic and prognostic applications stemming therefrom are also provided.
Resumen de: US20260306439A1
The present disclosure is directed to methods of promoting phagocytosis, particularly the phagocytic activity of microglia via activation of triggering receptor expressed on myeloid cells 2 (TREM2). The present disclosure is also directed to methods of activating TREM2 in a cell, particularly a neuronal cell exhibiting an accumulation of a pathogenic protein. The present disclosure is directed to detecting an effect of a compound on the TREM2 activity as well.
Nº publicación: US20260309705A1 08/10/2026
Solicitante:
SANOFI [FR]
Sanofi
Resumen de: US20260309705A1
Provided herein are methods for monitoring treatment for multiple sclerosis in a pregnant subject, and determining the efficacy of a treatment for multiple sclerosis in a pregnant subject. These methods include (a) extracting a drug from a dried blood spot (DBS) sample from a pregnant subject after a treatment for multiple sclerosis has been administered to the pregnant subject; (b) performing mass spectrometry on the extracted DBS sample; (c) determining a peak area ratio of the extracted DBS sample to an internal standard; and (d) identifying the administered treatment as being below the internal standard threshold if the plasma concentration of the treatment is less than 1 as compared to the internal standard ratio. Also provided herein are dried blood spot cards, and kits that include a dried blood spot card pre-treated with at least one internal standard.
BOPI
Sede Electrónica
